{"_id": "650d0ed6c9669d2e208ec2d6", "and": [{"$and": [{"cancer type": "melanoma"}, {"metastasized to the brain": true}]}, {"$and": [{"primary origin": {"$in": ["cutaneous", "acral/mucosal", "unknown"]}}, {"uveal primary": {"$ne": true}}]}, {"BRAF-V600 mutant melanoma": true}, {"$and": [{"MRI of the brain within 28 days prior to registration": true}, {"central nervous system metastases with at least one measurable brain metastasis >= 0.5 cm in size": true}, {"recommended MRI acquisition protocol": true}, {"CT of the head cannot substitute for brain MRI": true}, {"CNS disease documented on both Brain Metastases Baseline Tumor Assessment Form and Baseline Tumor Assessment Form": true}]}, {"$and": [{"measurable or non-measurable extracranial disease": true}, {"measurable disease assessed within 28 days prior to randomization": true}, {"non-measurable disease assessed within 42 days prior to randomization": true}, {"disease documented on Baseline Tumor Assessment Form": true}, {"CNS disease documented on both Brain Metastases Baseline Tumor Assessment Form and Baseline Tumor Assessment Form": true}]}, {"leptomeningeal disease": true}, {"corticosteroids for brain metastases at a dose of up to 8 mg of dexamethasone per day": true}, {"Zubrod performance status =< 2": true}, {"complete history and physical examination within 28 days prior to randomization": true}, {"able to swallow and retain pills": true}, {"hemoglobin >= 8.0 g/dL": true}, {"absolute neutrophil count >= 1,500/mcL": true}, {"platelets >= 75,000/mcL": true}, {"total bilirubin =< 1.5 institutional upper limit of normal (ULN)": true}, {"AST and ALT =< 2.5 x institutional ULN": true}, {"creatinine =< 2.0 institutional ULN": true}, {"$and": [{"known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents": true}, {"clinical risk assessment of cardiac function using the New York Heart Association Functional Classification": true}, {"NYHA class =< 2B": true}]}, {"$and": [{"prior or concurrent malignancy whose natural history or treatment does not interfere with safety or efficacy assessment": true}, {"eligible for this trial": true}]}, {"$and": [{"known human immunodeficiency virus (HIV)-infection": true}, {"on effective anti-retroviral therapy and undetectable viral load": true}]}, {"$and": [{"known history of hepatitis C virus (HCV) infection": true}, {"treated and cured": true}, {"undetectable HCV viral load prior to randomization": true}]}, {"participate in image banking": true}, {"opportunity to participate in specimen and blood collections": true}, {"informed consent in accordance with institutional and federal guidelines": true}, {"institutional review board approval within 365 days": true}], "$not": {"$or": [{"prior systemic therapy for metastatic disease": true}, {"prior radiation therapy within 7 days prior to randomization": true}, {"additional form of systemic anti-tumor therapy for melanoma while on protocol treatment": true}, {"use of hormonal contraceptives": true}, {"serious active infection requiring systemic therapy": true}, {"active autoimmune disease requiring treatment with biologic disease modifying agents": true}, {"grade 3 or 4 immune-related adverse events on ipilimumab or nivolumab requiring immune suppression with corticosteroids": true}, {"adverse events related to encorafenib and/or binimetinib requiring discontinuation of one or both drugs": true}, {"pregnant or nursing": true}, {"known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, clinical risk assessment of cardiac function using the New York Heart Association Functional Classification, NYHA class =< 2B": true}, {"prior or concurrent malignancy interfering with safety or efficacy assessment": true}, {"known human immunodeficiency virus (HIV)-infection on effective anti-retroviral therapy and undetectable viral load": true}, {"known history of hepatitis C virus (HCV) infection treated and cured, undetectable HCV viral load prior to randomization": true}]}, "nctId": "NCT04511013", "title": "A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases"}